 OncoSec Medical Incorporated OncoSec Nasdaq: ONCS, a company developing late-stage intratumoral cancer immunotherapies, today announced pre-clinical data from a feasibility study of its visceral lesion applicator VLA electroporation device and APOLLO generator which were presented online at the Annual Meeting of the Society of Interventional Radiology SIR. The feasibility study demonstrated the capability of a rigid, trocar-like VLA applicator to safely deliver and electroporate DNA-based immunotherapy directly into target organs in a large animal model using a CT-guided approach and OncoSecs new, lower voltage APOLLO generator. 